19 August 2019
Visiongain has launched a new pharma report Pharmaceutical Contract Manufacturing Market 2019-2029: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.
The contract manufacturing sector is more mature than other sectors of the pharma outsourcing industry and has therefore grown more slowly in recent years. Additionally, external factors such as pharma industry M&A, blockbuster patent expiries and limited funding for pharma development programmes, resulting from the global economic crisis that began in 2008, have restrained growth in the market in the last five years. However, growth continues to be driven by the pharma industry’s need to cut development and manufacturing costs, with a view to improving profitability and allowing companies to focus on core competencies, such as drug discovery and development.
The lead analyst of the report commented "The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies. Many CMOs are investing in single-use technologies for biopharma manufacturing, as this provides a lower-cost solution for producing biological drugs, through continuous manufacturing processes. Microreactors will offer similar advantages in API manufacturing and CMOs will become more interested in continuous processes which are quicker, lower cost, more flexible and allow lower volume production. Other in-demand technologies will include spray drying, which will provide a cheaper alternative to lyophilisation. Spray drying also has the additional advantage of offering continuous manufacturing, Visiongain notes."
Leading companies featured in the report include Boehringer Ingelheim BioXcellence, Catalent, DPx Holdings (formerly DSM and Patheon), Evonik Degussa, Famar, Fareva, Lonza, Mylan, Teva, Vetter Pharma and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.